Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation[1].
Basiliximab specifically inhibits T lymphocyte proliferation by binding to the IL-2Rα[1].
Basiliximab binds only to activated lymphocytes and macrophages/monocytes[3].
Basiliximab does not affect resting T lymphocytes that do not express IL-2Rα[3].
Basiliximab (CHI 621) (0.07 mg/rat; i.v.; once) decreases total placental natural killer cells in reduced uterine perfusion pressure (RUPP) rats[2].
| Animal Model: | Timed-pregnant Sprague Dawley (SD) rats, reduced uterine perfusion pressure (RUPP) rat model of placental ischemia[2] |
| Dosage: | 0.07 mg/rat |
| Administration: | IV infusion, once |
| Result: | Decreased total placental natural killer cells. Had no effect to lower MAP or improve pup weight and placental weight. |